Lead Sponsor

Lin Chen

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

•The subjects voluntarily joined this study and signed an informed consent form
•Locally advanced gastric or gastroesophageal junction adenocarcinoma confirmed by pathology or histology as HER-2 negative (cT2-4N+M0 Phase II-III)
•The primary lesion can be surgically removed, and the patient is willing to receive surgical treatment
•There are measurable solid tumors (efficacy evaluation standard: RECIST 1.1)
•Tumor evaluation should be conducted through CT scanning or MRI within 28 days before treatment
•ECOG score 0-1
•Life expectancy ≥ 12 months.

•Preoperative imaging examination indicates distant or peritoneal metastasis in patients
•Subjects with any known active autoimmune disease
•Serious cardiovascular disease
•The serum of the subjects tested positive for HIV
•Active hepatitis B (HbsAg positive and HBV-DNA ≥ 10 \^ 3copies/mL) or active hepatitis C (HCV antibody positive and HCV-DNA positive, requiring antiviral treatment at the same time)
•Known subjects with previous allergies to macromolecular protein formulations/monoclonal antibody components, or other contraindications to immunotherapy or chemotherapy
•Have a history of alcohol, drug, or substance abuse
•Individuals with a clear history of neurological or mental disorders, such as epilepsy, dementia, and poor compliance

Related studies

NCT05593458 · Locally Advanced Gastric Carcinoma

NCT06932068 · HER2 Negative, Low PD-L1 Expressing, and more

NCT07123194 · Digital Addiction, Art Therapy, and more

NCT05937750 · Long Term Efficacy and Safety

NCT04389632 · Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, and more

Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer